FNCH Pengajuan SEC - Finch Therapeutics Group, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1733257

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Finch Therapeutics Group, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

November 12, 2024	15-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 OMB APPROVAL OMB Number: 3235-0167 Expires: August 31, 2027 Estimated average burden hours per response: 1.
November 1, 2024	S-8 POS	As filed with the Securities and Exchange Commission on November 1, 2024 As filed with the Securities and Exchange Commission on November 1, 2024 Registration No.
November 1, 2024	S-8 POS	As filed with the Securities and Exchange Commission on November 1, 2024 As filed with the Securities and Exchange Commission on November 1, 2024 Registration No.
November 1, 2024	S-8 POS	As filed with the Securities and Exchange Commission on November 1, 2024 As filed with the Securities and Exchange Commission on November 1, 2024 Registration No.
November 1, 2024	POS AM	As filed with the Securities and Exchange Commission on November 1, 2024 As filed with the Securities and Exchange Commission on November 1, 2024 Registration No.
October 31, 2024	25	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-40227 Finch Therapeutics 25 OMB APPROVAL OMB Number: 3235-0080 Expires: May 31, 2027 Estimated average burden hours per response: 1.
October 21, 2024	EX-99.1	Finch Announces Delisting from Nasdaq and SEC Deregistration Exhibit 99.1 Finch Announces Delisting from Nasdaq and SEC Deregistration Boston, MA, October 21, 2024 (GLOBE NEWSWIRE) — Finch Therapeutics Group, Inc. (Nasdaq: FNCH) (“Finch” or the “Company”), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced that it has provided notification to The Nasdaq Stock Market, LLC (“Nasdaq”) of its intent
October 21, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2024 FINCH THERAPEUTICS GROUP, INC (Exact name of registrant as specified in its charter) Delaware 001-40227 82-3433558 (State or other jurisdiction of incorporation) (Com
August 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40227 FINCH THERAPEUTICS GROUP, INC.
August 12, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2024 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Comm
May 24, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Finch Therapeutics G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Commis
May 17, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Commis
May 10, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40227 FINCH THERAPEUTICS GROUP, INC.
April 26, 2024	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2023 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-40227 FINCH THERAPEUTICS GROUP, INC. (Exact
April 3, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Comm
March 25, 2024	EX-10.12	Consulting Agreement with Mark Smith, dated May 25, 2023. Exhibit 10.12 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Agreement”) is made and entered into as of May 16, 2023 (the “Effective Date”) by and between Mark Smith, with an address of [***] (“Consultant”), and Finch Therapeutics, Inc., a Delaware corporation with an address at 200 Inner Belt Road, Suite 400, Somerville, MA 02143 (“Finch”). Finch desires to obtain from Consultant various se
March 25, 2024	EX-10.15	Retention Bonus Agreement by and between Finch Therapeutics Group, Inc. and Marc Blaustein, dated as December 7, 2022 Exhibit 10.15 RETENTION BONUS AGREEMENT THIS RETENTION BONUS AGREEMENT (this “Agreement”), is made and entered into by and between Finch Therapeutics Group, Inc., a Delaware corporation (together with all subsidiaries and affiliates hereinafter referred to as the “Company”), and Marc Blaustein (the “Executive”) effective as of December 7, 2022. 1. Retention Bonus. a. Service Based-Bonus. The Execu
March 25, 2024	EX-10.14	Amendment No. 1 to the Executive Employment Agreement by and between Finch Therapeutics Group, Inc. and Marc Blaustein, dated as of December 7, 2022. Exhibit 10.14 December 7, 2022 Marc Blaustein [email protected] Dear Marc, The purpose of this letter is to amend the Employment Agreement by and between Finch Therapeutics Group, Inc. (the “Company”) and you dated as of September 8, 2021 (the “Employment Agreement”), effective as of April 30, 2022 (the “Effective Date”). Capitalized terms used but not defined in this letter will ha
March 25, 2024	EX-21.1	Subsidiaries of Finch Therapeutics Group, Inc. Exhibit 21.1 SUBSIDIARIES Name Jurisdiction of Formation Finch Therapeutics, Inc. Delaware Finch Therapeutics Holdings, LLC Delaware Finch Research and Development, LLC Delaware
March 25, 2024	EX-97.1	Policy for Recoupment of Incentive Compensation Exhibit 97.1 FINCH THERAPEUTICS GROUP, INC. Policy for Recoupment of Incentive Compensation 1. Introduction In accordance with Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the regulations thereunder, the Board of Directors (the “Board”) of Finch Therapeutics Group, Inc. (the “Company”) has adopted this policy (the “Policy”) providing for the Company’s re
March 25, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K b UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40227 FINCH THERAPE
February 23, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2024 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (C
December 13, 2023	SC 13G	FNCH / Finch Therapeutics Group Inc / Ugwumba Chidozie - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. 1) Finch Therapeutics Group, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 31773D101 (CUSIP Number) Decembe
November 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 Finch Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (C
November 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40227 FINCH THERAPEUTICS GROUP, INC.
August 11, 2023	EX-10.7	2021 Employee Stock Purchase Plan, as amended. EXHIBIT 10.7 FINCH THERAPEUTICS GROUP, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 11, 2021 APPROVED BY THE STOCKHOLDERS: MARCH 11, 2021 IPO DATE: MARCH 18, 2021 AMENDED AND RESTATED AS OF: JUNE 8, 2023 1. General; Purpose. (a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to pur
August 11, 2023	EX-10.1	Amendment to the Amended and Restated Exclusive License Agreement, dated as of April 12, 2023, between Finch Therapeutics Holdings LLC and Regents of the University of Minnesota. DocuSign Envelope ID: C23403EF-A3D5-465F-8315-7AD59052E3C4 Agreement #: A20120373 EXHIBIT 10.
August 11, 2023	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No.
August 11, 2023	EX-10.5	2017 Equity Incentive Plan, as amended, and the forms of agreements thereunder. EXHIBIT 10.5 FINCH THERAPEUTICS GROUP, INC. 2017 EQUITY INCENTIVE PLAN AMENDED AND RESTATED AS OF: JUNE 8, 2023 1. Definitions As used in this 2017 Equity Incentive Plan, the following terms shall have the respective meanings set out below, unless the context clearly requires otherwise: 1.1. “Accelerate,” “Accelerated,” and “Acceleration,” when used with respect to an Option, means that as of the
August 11, 2023	EX-10.6	2021 Equity Incentive Plan, as amended, and the forms of agreements thereunder. EXHIBIT 10.6 FINCH THERAPEUTICS GROUP, INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 11, 2021 APPROVED BY THE STOCKHOLDERS: MARCH 11, 2021 IPO DATE: MARCH 18, 2021 AMENDED AND RESTATED AS OF: JUNE 8, 2023 1. GENERAL. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives
August 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40227 FINCH THERAPEUTICS GROUP, INC.
August 10, 2023	EX-10.6	2021 Equity Incentive Plan, as amended, and the forms of agreements thereunder (incorporated by reference to Exhibit 10.6 of the Registrant’s Quarterly Report on Form 10-Q filed August 10, 2023). EXHIBIT 10.6 FINCH THERAPEUTICS GROUP, INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 11, 2021 APPROVED BY THE STOCKHOLDERS: MARCH 11, 2021 IPO DATE: MARCH 18, 2021 AMENDED AND RESTATED AS OF: JUNE 8, 2023 1. GENERAL. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives
August 10, 2023	EX-10.5	2017 Equity Incentive Plan, as amended, and the forms of agreements thereunder. EXHIBIT 10.5 FINCH THERAPEUTICS GROUP, INC. 2017 EQUITY INCENTIVE PLAN AMENDED AND RESTATED AS OF: JUNE 8, 2023 1. Definitions As used in this 2017 Equity Incentive Plan, the following terms shall have the respective meanings set out below, unless the context clearly requires otherwise: 1.1. “Accelerate,” “Accelerated,” and “Acceleration,” when used with respect to an Option, means that as of the
August 10, 2023	EX-10.7	2021 Employee Stock Purchase Plan, as amended. EXHIBIT 10.7 FINCH THERAPEUTICS GROUP, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 11, 2021 APPROVED BY THE STOCKHOLDERS: MARCH 11, 2021 IPO DATE: MARCH 18, 2021 AMENDED AND RESTATED AS OF: JUNE 8, 2023 1. General; Purpose. (a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to pur
July 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 Finch Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Commi
June 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 Finch Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Commi
June 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 Finch Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Commi
June 9, 2023	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Commis
June 9, 2023	EX-3.1	Certificate of Amendment to the Amended and Restated Certificate of Incorporation. EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF FINCH THERAPEUTICS GROUP, INC. Finch Therapeutics Group, Inc., a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY: FIRST: The name of the Corporation is: Finch Therapeutics Group, Inc. SECOND: The Corporat
May 30, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 Finch Therapeutics G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Commis
May 18, 2023	EX-10.1	Amendment to the Amended and Restated Exclusive License Agreement, dated as of April 12, 2023, between Finch Therapeutics Holdings LLC and Regents of the University of Minnesota. EX-10.1 Exhibit 10.1 EXECUTION VERSION LEASE TERMINATION AGREEMENT THIS LEASE TERMINATION AGREEMENT dated as of May 12, 2023 (this “Agreement”), is entered into by and between NRL WSC 200 Inner Belt Prop, LLC, a Delaware limited liability company (“Landlord”), and Finch Therapeutics, Inc., a Delaware corporation (“Tenant”; Tenant and Landlord are each, individually, referred to herein as a “Party”
May 18, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 Finch Therapeutics G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Commis
May 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2023 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Commis
May 11, 2023	EX-16.1	Letter of Deloitte & Touche LLP, dated May 11, 2023 (incorporated by reference to Exhibit 16.1 of the Exhibit 16.1 Deloitte & Touche LLP 200 Berkeley Street Boston, MA 02116 USA Tel.: +1 617 473 2000 www.deloitte.com May 11, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 Dear Sirs/Madams: We have read Item 4.01 of Finch Therapeutics Group, Inc.'s Form 8-K dated May 11, 2023, and have the following comments: 1. We agree with the statements made in paragraphs
May 11, 2023	DEFA14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) DEFA14A 1 fnchdefa14asupplementa.htm DEFA14A SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Defi
May 10, 2023	EX-99	Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates Exhibit 99.1 Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates SOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) - Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today reported first quarter 2023 financial resul
May 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Commis
May 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40227 FINCH THERAPEUTICS GROUP, INC.
April 26, 2023	DEF 14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 26, 2023	DEFA14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 25, 2023	EX-99	Finch Therapeutics Announces Executive Leadership Transitions Matthew P. Blischak, an experienced life sciences executive and intellectual property counsel, appointed as Chief Executive Officer effective May 16, 2023; Mark Smith, PhD, to complete his Exhibit 99.1 Finch Therapeutics Announces Executive Leadership Transitions Matthew P. Blischak, an experienced life sciences executive and intellectual property counsel, appointed as Chief Executive Officer effective May 16, 2023; Mark Smith, PhD, to complete his time as CEO effective May 15 Lance Thibault, Managing Director of Danforth Advisors, to serve as Chief Financial Officer effective May 1
April 25, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2023 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Comm
April 25, 2023	EX-10	Executive Employment Agreement, effective as of April 21, 2023, between Finch Therapeutics Group, Inc. and Matthew Blischak. Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT, (this “Agreement”), is made by and between Finch Therapeutics Group, Inc., a Delaware corporation (“FTG”, together with all subsidiaries and affiliates hereinafter referred to as the “Company”), and Matthew P. Blischak (the “Executive”). WHEREAS, the Company desires to employ the Executive as its Chief Executive Offic
April 25, 2023	EX-10	Consulting Agreement, dated as of April 21, 2023, between Finch Therapeutics, Inc. and Matthew P. Blischak (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K, filed April 25, 2023). Exhibit 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Agreement”) is made and entered into as of April 21, 2023 (the “Effective Date”) by and between Matthew Blischak, with an address of [***] (“Consultant”), and Finch Therapeutics, Inc., a Delaware corporation with an address at 200 Inner Belt Road, Suite 400, Somerville, MA 02143 (“Finch”). Finch desires to obtain from Consultant var
April 18, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2023 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Comm
April 18, 2023	EX-99	Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement Exhibit 99.1 Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement SOMERVILLE, Mass., April 18, 2023 (GLOBE NEWSWIRE) - Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property
April 14, 2023	PRE 14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 23, 2023	EX-FILING FEES	Filing fee table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 Finch Therapeutics Group, Inc.
March 23, 2023	EX-10	Retention Bonus Agreement by and between Finch Therapeutics Group, Inc. and Marc Blaustein, dated as December 7, 2022. Exhibit 10.15 RETENTION BONUS AGREEMENT THIS RETENTION BONUS AGREEMENT (this “Agreement”), is made and entered into by and between Finch Therapeutics Group, Inc., a Delaware corporation (together with all subsidiaries and affiliates hereinafter referred to as the “Company”), and Marc Blaustein (the “Executive”) effective as of December 7, 2022. 1. Retention Bonus. a. Service Based-Bonus. The Execu
March 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Comm
March 23, 2023	EX-10	Amendment No. 1 to the Executive Employment Agreement by and between Finch Therapeutics Group, Inc. and Marc Blaustein, dated as of December 7, 2022. Exhibit 10.14 December 7, 2022 Marc Blaustein [email protected] Dear Marc, The purpose of this letter is to amend the Employment Agreement by and between Finch Therapeutics Group, Inc. (the “Company”) and you dated as of September 8, 2021 (the “Employment Agreement”), effective as of April 30, 2022 (the “Effective Date”). Capitalized terms used but not defined in this letter will ha
March 23, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K b UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40227 FINCH THERAPE
March 23, 2023	EX-99	Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates Exhibit 99.1 Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates SOMERVILLE, Mass., March 23, 2023 (GLOBE NEWSWIRE) - Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today reported fourth quarter an
March 23, 2023	S-8	As filed with the Securities and Exchange Commission on March 23, 2023. S-8 As filed with the Securities and Exchange Commission on March 23, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Finch Therapeutics Group, Inc. (Exact name of Registrant as specified in its charter) Delaware 82-3433558 (State or other jurisdiction of incorporation or organizati
March 23, 2023	EX-21	Subsidiaries of Finch Therapeutics Group, Inc. Exhibit 21.1 SUBSIDIARIES Name Jurisdiction of Formation Finch Therapeutics, Inc. Delaware Finch Therapeutics Holdings, LLC Delaware Finch Research and Development, LLC Delaware
January 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2023 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Co
January 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2023 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Co
January 24, 2023	EX-99.1	Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets Exhibit 99.1 Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets SOMERVILLE, Mass., January 24, 2023 (GLOBE NEWSWIRE) - Finch Therapeutics Group, Inc. (the “Company,” “Finch,” or “Finch Therapeutics”) (Nasdaq: FNCH) today announced its decision to discontinue the PRISM4 Phase 3 trial of CP
January 6, 2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 06, 2023 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Co
December 12, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (C
November 14, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (C
November 14, 2022	EX-99.1	Forward-Looking Statements Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such a CORPORATE PRESENTATION \| NOVEMBER 2022 Harnessing the Microbiome to Transform Lives Exhibit 99.
November 10, 2022	EX-10.1	Amendment No. 3, dated October 19, 2022, to the Amended and Restated Agreement by and between Finch Therapeutics, Inc. and Millennium Pharmaceuticals, Inc., dated as of October 21, 2019 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE FINCH THERAPEUTICS GROUP, INC.
November 10, 2022	EX-99.1	Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results Exhibit 99.1 Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results ? Patient dosing underway in PRISM4 Phase 3 trial of CP101 in recurrent CDI ? Topline PRISM4 data anticipated in H1 2024 ? Anticipated cash runway into Q2 2024 SOMERVILLE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) - Finch Therapeutics Group, Inc. (?Finch? or ?Finch Therapeutics?) (Nasdaq: FNCH),
November 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (C
November 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40227 FINCH THERAPEUTICS GROUP, INC.
September 1, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 01, 2022 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (
September 1, 2022	EX-99.1	Finch Therapeutics Provides Business Update Exhibit 99.1 Finch Therapeutics Provides Business Update SOMERVILLE, Mass., Sept. 1, 2022 (GLOBE NEWSWIRE) - Finch Therapeutics Group, Inc. (?Finch? or ?Finch Therapeutics?) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery? platform to develop a novel class of orally administered biological drugs, today announced plans to reduce its workforce by
August 25, 2022	EX-99.1	Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD Exhibit 99.1 Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD SOMERVILLE, Mass., August 25, 2022 (GLOBE NEWSWIRE) - Finch Therapeutics Group, Inc. (?Finch? or ?Finch Therapeutics?) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery? platform to develop a novel class of oral
August 25, 2022	8-K	Regulation FD Disclosure, Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2022 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Com
August 11, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40227 FINCH THERAPEUTICS GROUP, INC.
August 11, 2022	EX-99.1	Finch Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results Exhibit 99.1 Finch Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results ? On track to proceed with enrollment in PRISM4 Phase 3 trial of CP101 in recurrent CDI in H2 2022 ? On track to submit IND for FIN-211 in children with autism and significant GI symptoms in Q4 2022 ? Additional results from PRISM-EXT Phase 2 trial of CP101 in recurrent CDI accepted for pre
August 11, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Com
June 16, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Commi
May 31, 2022	CORRESP	FINCH THERAPEUTICS GROUP, INC. 200 Inner Belt Road, Suite 400 Somerville, MA 02143 FINCH THERAPEUTICS GROUP, INC. 200 Inner Belt Road, Suite 400 Somerville, MA 02143 May 31, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Re: Finch Therapeutics Group, Inc. Registration Statement on Form S-3 (File No. 333-265173) Request for Acceleration Ladies and Gentlem
May 24, 2022	EX-1.2	Open Market Sale Agreement, dated as of May 24, 2022, between Finch Therapeutics Group, Inc. and Jefferies LLC Exhibit 1.2 OPEN MARKET SALE AGREEMENT May 24, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Finch Therapeutics Group, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.
May 24, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Finch Therapeutics Group, Inc.
May 24, 2022	EX-4.8	Form of Indenture Table of Contents Exhibit 4.8 FINCH THERAPEUTICS GROUP, INC. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of [ ], [ ] Table of Contents TABLE OF CONTENTS ARTICLE 1. DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1. DEFINITIONS 1 1.2. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 5 1.3. RULES OF CONSTRUCTION 5 ARTICLE 2. THE SECURITIES 6 2.1. ISSUABLE IN SERI
May 24, 2022	S-3	As filed with the Securities and Exchange Commission on May 24, 2022. Table of Contents As filed with the Securities and Exchange Commission on May 24, 2022.
May 16, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Commis
May 16, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40227 FINCH THERAPEUTICS GROUP, INC.
May 16, 2022	EX-10.1	Loan and Security Agreement, dated May 11, 2022, by and among Finch Therapeutics Group, Inc. and each of its Subsidiaries, the several banks and other financial institutions or entities from time to time parties thereto, and Hercules Capital, Inc. Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED By [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of May 11, 2022 and is entered into by and among Finch Therapeutics Group, Inc., a Delaware corporation,
May 16, 2022	EX-99.2	Forward-Looking Statements Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such a Harnessing the Genomic Revolution & Machine Learning to Pioneer Microbiome Therapeutics CORPORATE UPDATE \| MAY 2022 Exhibit 99.
May 16, 2022	EX-99.1	Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results Exhibit 99.1 Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results ? FDA lifted clinical hold on IND for CP101 ? Enrollment in PRISM4 Phase 3 trial of CP101 in recurrent CDI expected to proceed in H2 2022 ? $15 million drawn from new $55 million term debt facility ? Anticipated cash runway into Q2 2024 ? Corporate update call today at 8am ET SOMERVILLE, Mass
April 28, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2022 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Comm
April 28, 2022	EX-99.1	Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND Exhibit 99.1 Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND SOMERVILLE, Mass., April 28, 2022 (GLOBE NEWSWIRE) - Finch Therapeutics Group, Inc. (?Finch? or ?Finch Therapeutics?) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery? platform to develop a novel class of orally administered biological drugs, today announced that
April 26, 2022	DEF 14A	Definitive Proxy Statement SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 26, 2022	DEFA14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 19, 2022	EX-99.1	Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs Exhibit 99.1 Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs SOMERVILLE, Mass., April 19, 2022 (GLOBE NEWSWIRE) - Finch Therapeutics Group, Inc. (?Finch? or ?Finch Therapeutics?) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery? platform to develop a novel class of orally administered biologica
April 19, 2022	8-K	Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2022 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Comm
March 31, 2022	EX-10.3	Amended and Restated Exclusive License Agreement between Regents of the University of Minnesota and Finch Therapeutics Holdings LLC, dated January 28, 2022 (incorporated by reference to Exhibit 10.3 of the Registrant’s Annual Report on Form 10-K, filed March 31, 2022). OTC Agreement Number: [*] OTC Case Number: [] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE FINCH THERAPEUTICS GROUP, INC.
March 31, 2022	EX-99.1	Finch Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates Exhibit 99.1 Finch Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates SOMERVILLE, Mass., March 31, 2022 (GLOBE NEWSWIRE) - Finch Therapeutics Group, Inc. (?Finch? or ?Finch Therapeutics?) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery? platform to develop a novel class of orally administered
March 31, 2022	EX-10.7	Amendment No. 2, dated November 12, 2021, to the Amended and Restated Agreement by and between Finch Therapeutics, Inc. and Millennium Pharmaceuticals, Inc. dated as of October 21, 2019. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE FINCH THERAPEUTICS GROUP, INC.
March 31, 2022	S-8	As filed with the Securities and Exchange Commission on March 31, 2022. As filed with the Securities and Exchange Commission on March 31, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Finch Therapeutics Group, Inc. (Exact name of Registrant as specified in its charter) Delaware 82-3433558 (State or other jurisdiction of incorporation or organization)
March 31, 2022	EX-4.3	Description of Registrant’s Securities (incorporated by reference to Exhibit 4.3 of the Registrant’s Annual Report on Form 10-K, filed March 31, 2022). Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our capital stock is a summary and does not purport to be complete. It is subject to, and qualified in its entirety by reference to, the applicable provisions of our amended and restated certificate of incorporation, our amended and restated b
March 31, 2022	EX-10.17	Release Agreement, dated November 4, 2021, by and between Finch Therapeutics Group, Inc. and Zain Kassam. Exhibit 10.17 Release Agreement I, Zain Kassam, understand and agree completely to the terms set forth in this Release Agreement (the ?Release?) and in the Amended and Restated Executive Employment Agreement (the ?Employment Agreement?) dated March 12, 2021, by and between Finch Therapeutics Group, Inc. (?Company?) and me, as a result of my voluntary resignation without Good Reason effective on No
March 31, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Comm
March 31, 2022	EX-FILING FEES	Filing fee table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 Finch Therapeutics Group, Inc.
March 31, 2022	EX-10.19	Executive Employment Agreement by and between Finch Therapeutics Group, Inc. and Marc Blaustein, dated as of September 8, 2021 (incorporated by reference to Exhibit 10.19 of the Registrant’s Annual Report on Form 10-K, filed March 31, 2022). Exhibit 10.19 EXECUTIVE EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT, dated as of September 8, 2021 (this ?Agreement?), is made by and between Finch Therapeutics Group, Inc., a Delaware corporation (?FTG?, together with all subsidiaries and affiliates hereinafter referred to as the ?Company?), and Marc Blaustein (the ?Executive?). WHEREAS, the Company desires to em
March 31, 2022	EX-10.20	Amended and Restated Executive Employment Agreement by and between Finch Therapeutics Group, Inc. and Joseph Vittiglio, dated as of March 12, 2021 Exhibit 10.20 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT, dated as of March 12, 2021 (this ?Agreement?), is made by and between Finch Therapeutics Group, Inc., a Delaware corporation (?FTG?, together with all subsidiaries and affiliates hereinafter referred to as the ?Company?), and Joseph Vittiglio (the ?Executive?). WHEREAS, the C
March 31, 2022	EX-10.21	Amendment No. 1 to the Amended and Restated Executive Employment Agreement by and between Finch Therapeutics Group, Inc. and Joseph Vittiglio, dated as of March 18, 2021 Exhibit 10.21 AMENDMENT NO. 1 TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDMENT NO. 1 TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this ?New Amendment?) is made as of March 18, 2021, by and between Finch Therapeutics Group, Inc., a Delaware corporation (?FTG?, together with all subsidiaries and affiliates hereinafter referred to as the ?Company?), and Joseph Vittigli
March 31, 2022	EX-21.1	Subsidiaries of Finch Therapeutics Group, Inc. Exhibit 21.1 SUBSIDIARIES Name Jurisdiction of Formation Finch Therapeutics, Inc. Delaware Finch Therapeutics Holdings, LLC Delaware Finch Research and Development, LLC Delaware
March 31, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40227 FINCH THERAPEUT
March 1, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (C
March 1, 2022	EX-99.1	Finch Therapeutics Provides an Update on its Phase 3 Trial of CP101 in Recurrent C. difficile Infection Exhibit 99.1 Finch Therapeutics Provides an Update on its Phase 3 Trial of CP101 in Recurrent C. difficile Infection SOMERVILLE, Mass., March 1, 2022 (GLOBE NEWSWIRE) ? Finch Therapeutics Group, Inc. (?Finch? or ?Finch Therapeutics? or ?Company?) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery? platform to develop a novel class of orally admini
February 14, 2022	SC 13G	FNCH / Finch Therapeutics Group, Inc. / Ugwumba Chidozie - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. ) Finch Therapeutics Group, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 31773D101 (CUSIP Number) December
February 14, 2022	SC 13G	FNCH / Finch Therapeutics Group, Inc. / Walton Thomas Layton - SCHEDULE 13G, AMENDMENT 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) Finch Therapeutics Group, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Sec
January 10, 2022	EX-99.1	Forward-Looking Statements Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such a Harnessing the Genomic Revolution & Machine Learning to Pioneer Microbiome Therapeutics CORPORATE PRESENTATION \| JANUARY 2022 Exhibit 99.
January 10, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Co
November 10, 2021	EX-10.2	Lease, dated August 3, 2021, by and between Hood Park LLC and Finch Therapeutics, Inc. Exhibit 10.2 LEASE LANDLORD: Hood Park LLC, a Massachusetts limited liability company TENANT: Finch Therapeutics, Inc., a Delaware corporation PREMISES: Hood Park, Charlestown, Massachusetts DATED: August 3, 2021 TABLE OF CONTENTS ARTICLE CAPTION PAGE ARTICLE I 5 (A) SUBJECTS REFERRED TO: 5 (B) EXHIBITS 8 ARTICLE II 8 (A) DEMISED PREMISES 8 (B) COMMON AREAS 8 (C) PARKING 9 ARTICLE III 13 (A) TERM
November 10, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40227 FINCH THERAPEUTICS GROUP, INC.
November 10, 2021	EX-99.1	Finch Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates Exhibit 99.1 Finch Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates ? New positive topline data from 132-participant PRISM-EXT Phase 2 open-label trial of CP101 in recurrent C. difficile infection (CDI) show 80.3% sustained clinical cure rate through 8 weeks, with a similar rate maintained through 24 weeks ? New data presented at ACG annual meeting from PRISM
November 10, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (C
November 10, 2021	EX-99.2	Forward-Looking Statements Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such a EX-99.2 3 fnch-ex992.htm EX-99.2 Harnessing the Genomic Revolution & Machine Learning to Pioneer Microbiome Therapeutics CORPORATE PRESENTATION \| NOVEMBER 2021 Exhibit 99.2 Forward-Looking Statements Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, a
November 10, 2021	EX-10.1	Amendment, dated August 9, 2021, to the Amended and Restated Agreement, by and between Finch Therapeutics, Inc. and Millennium Pharmaceuticals, Inc., dated as of October 21, 2019 Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE FINCH THERAPEUTICS GROUP, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO FINCH THERAPEUTICS GROUP, INC. IF PUBLICLY DISCLOSED. AMENDMENT TO AMENDED AND RESTATED AGREEMENT This Amendment to Amended and Restated Agreement (this ?
October 19, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2021 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Co
October 19, 2021	EX-99.1	Forward-Looking Statements Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such a EX-99.1 2 fnch-ex991.htm EX-99.1 Harnessing the Genomic Revolution & Machine Learning to Pioneer Microbiome Therapeutics Jefferies Virtual Next Generation IBD Therapeutics Summit October 2021 Exhibit 99.1 Forward-Looking Statements Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities
October 5, 2021	EX-99.1	Finch Therapeutics Appoints Samuel Allen Hamood to its Board of Directors EX-99.1 2 d222985dex991.htm EX-99.1 Exhibit 99.1 Finch Therapeutics Appoints Samuel Allen Hamood to its Board of Directors SOMERVILLE, Mass., October 5, 2021 (GLOBE NEWSWIRE) — Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administere
October 5, 2021	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2021 (October 1, 2021) Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of I
September 13, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2021 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (
September 13, 2021	EX-99.1	Forward-Looking Statements Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such a EX-99.1 2 fnch-ex991117.htm EX-99.1 Harnessing the Genomic Revolution & Machine Learning to Pioneer Microbiome Therapeutics CORPORATE PRESENTATION \| SEPTEMBER 2021 Exhibit 99.1 Forward-Looking Statements Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 199
September 8, 2021	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2021 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (C
September 8, 2021	EX-99.1	Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer EX-99.1 2 fnch-ex9916.htm EX-99.1 Exhibit 99.1 Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer SOMERVILLE, Mass., September 8, 2021 (GLOBE NEWSWIRE) - Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of or
August 10, 2021	EX-99	Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program EX-99 2 fnch-ex997.htm EX-99 Exhibit 99.1 Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program • Finch to transfer FIN-524 program to Takeda for clinical development • Finch and Takeda to continue discovery efforts targeting Crohn’s disease SOMERVILLE, Mass., August 10, 2021 (GLOBE NEWSWIRE) - Finch Therapeutics Group, Inc. (“Finch” or
August 10, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Com
August 10, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Com
August 10, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40227 FINCH THERAPEUTICS GROUP, INC.
August 10, 2021	EX-99.1	Finch Therapeutics Group, Inc. Condensed Consolidated Statements of Operations (Unaudited) (in thousands, except share and per share data) EX-99.1 2 fnch-ex9916.htm EX-99.1 Exhibit 99.1 Finch Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update • Takeda to accelerate leadership role in advancing FIN-524/TAK-524 ulcerative colitis development program • Topline safety and efficacy data from more than 130 recurrent CDI patients treated with CP101 in open label PRISM-EXT trial expected in H2 2021 • Cont
August 4, 2021	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 (August 3, 2021) Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Inc
May 13, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Commis
May 13, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40227 FINCH THERAPEUTICS GROUP, INC.
May 13, 2021	EX-99.1	Finch Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates Exhibit 99.1 Finch Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates ? Completed upsized IPO, raising $130.8 million in gross proceeds ? Topline safety and efficacy data from more than 130 recurrent CDI patients treated with CP101 in PRISM-EXT expected in H2 2021 ? Strengthened leadership team with the appointment of Susan E. Graf to Board of Directors, Michel
April 27, 2021	EX-99.1	Finch Therapeutics Appoints Susan E. Graf to Board of Directors Exhibit 99.1 Finch Therapeutics Appoints Susan E. Graf to Board of Directors SOMERVILLE, Mass., April 27, 2021 (GLOBE NEWSWIRE) - Finch Therapeutics Group, Inc. (?Finch? or ?Finch Therapeutics?) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today announced that Susan E
April 27, 2021	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2021 Finch Therapeutics Group, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40227 82-3433558 (State or Other Jurisdiction of Incorporation) (Comm
April 1, 2021	EX-99.1	Joint Filing Agreement, dated as of April 1, 2021 among Crestovo Investor LLC and Chris Shumway. EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of the attached statement on Schedule 13D and any amendments.
April 1, 2021	SC 13D	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Finch Therapeutics Group, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 31773D101 (CUSIP Number) Christian H. Lange c/o Crestovo Investor LLC 28 Havemeyer Place Greenwich, CT 06830 (203) 485-8550 (Name, Addr
March 29, 2021	EX-99.1	Form of Lock-Up Agreement EX-99.1 2 ex991.htm EX-99.1 Finch Therapeutics Group, Inc. Form of Lock-Up Agreement [●], 2020 BOFA SECURITIES, INC. JEFFERIES LLC EVERCORE GROUP L.L.C. as Representatives of the several Underwriters to be named in the within-mentioned Underwriting Agreement c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Evercore
March 29, 2021	SC 13D	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Finch Therapeutics Group, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Finch Therapeutics Group, Inc. - (Name of Issuer) - Common Stock, $0.001 par value per share - (Title of Class of Securities) 31773D101 - (CUSIP Number) Nicholas Haft OMX Ventures, LLC One Overlook Point, Suite 100 Lincolnshire, IL 60060 (847) 634-2389 -
March 26, 2021	SC 13G	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. )* SC 13G 1 ftg-sc13g032321.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. )* Finch Therapeutics Group, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 3177
March 26, 2021	EX-4.6	2021 Employee Stock Purchase Plan. EX-4.6 3 d101803dex46.htm EX-4.6 Exhibit 4.6 FINCH THERAPEUTICS GROUP, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 11, 2021 APPROVED BY THE STOCKHOLDERS: MARCH 11, 2021 IPO DATE: MARCH 18, 2021 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase sha
March 26, 2021	EX-4.5	2021 Equity Incentive Plan and the forms of agreements thereunder. Exhibit 4.5 FINCH THERAPEUTICS GROUP, INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 11, 2021 APPROVED BY THE STOCKHOLDERS: MARCH 11, 2021 IPO DATE: MARCH 18, 2021 1. GENERAL. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts
March 26, 2021	S-8	- S-8 As filed with the Securities and Exchange Commission on March 26, 2021 Registration No.
March 23, 2021	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2021 Finch Therapeutics Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40227 82-3433558 (state or other jurisdiction of incorporation) (Comm
March 23, 2021	EX-3.2	Amended and Restated Bylaws of Finch Therapeutics Group, Inc. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF FINCH THERAPEUTICS GROUP, INC. (A DELAWARE CORPORATION) Table of Contents Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS? MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meetings 1 Section 6. Special Meetings 5 Section 7. Notice
March 23, 2021	EX-3.1	Amended and Restated Certificate of Incorporation of Finch Therapeutics Group, Inc. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF FINCH THERAPEUTICS GROUP, INC. Finch Therapeutics Group, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of the Delaware, hereby certifies that: ONE: The original name of this corporation was Finch Therapeutics Group, Inc. and the date of filing the original Certificate of In
March 22, 2021	424B4	7,500,000 Shares Common Stock 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-253622 333-254475 PROSPECTUS 7,500,000 Shares Common Stock This is the initial public offering of Finch Therapeutics Group, Inc. We are selling 7,500,000 shares of our common stock. The public offering price is $17.00 per share. Currently, no public market exists for the shares. Our common stock has been approved for li
March 18, 2021	S-1/A	Form S-1 Table of Contents As filed with the Securities and Exchange Commission on March 18, 2021 Registration Statement No.
March 18, 2021	S-1MEF	- S-1MEF As filed with the Securities and Exchange Commission on March 18, 2021 Registration No.
March 16, 2021	CORRESP	FINCH THERAPEUTICS GROUP, INC. 200 Inner Belt Road, Suite 400 Somerville, Massachusetts 02143 CORRESP 1 filename1.htm FINCH THERAPEUTICS GROUP, INC. 200 Inner Belt Road, Suite 400 Somerville, Massachusetts 02143 March 16, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Tara Harkins Ms. Kate Tillan Ms. Margaret Schwartz Ms. Laura Crotty RE: Finch Therapeutics Group, Inc. Registration Statement on Form S-1 File
March 16, 2021	CORRESP	[Signature Page Follows] March 16, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Tara Harkins Ms. Kate Tillan Ms. Margaret Schwartz Ms. Laura Crotty Re: Finch Therapeutics Group, Inc. Registration Statement on Form S-1 File No. 333-253622 Acceleration Request Requested Date: March 18, 2021 Requested Time: 4:00 PM, Eastern Daylight
March 16, 2021	8-A12B	Form 8-A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(B) OR (G) OF THE SECURITIES EXCHANGE ACT OF 1934 Finch Therapeutics Group, Inc.
March 15, 2021	S-1/A	- S-1/A Table of Contents As filed with the Securities and Exchange Commission on March 15, 2021 Registration Statement No.
March 15, 2021	EX-10.11	2021 Employee Stock Purchase Plan. Exhibit 10.11 FINCH THERAPEUTICS GROUP, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 11, 2021 APPROVED BY THE STOCKHOLDERS: MARCH 11, 2021 IPO DATE: , 2021 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits t
March 15, 2021	EX-10.13	Amended and Restated Executive Employment Agreement by and between the registrant and Zain Kassam, dated as of March 12, 2021, to be effective upon the pricing of this offering. Exhibit 10.13 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT, dated as of March 12, 2021 (this “Agreement”), is made by and between Finch Therapeutics Group, Inc., a Delaware corporation (“FTG”, together with all subsidiaries and affiliates hereinafter referred to as the “Company”), and Zain Kassam (the “Executive”). WHEREAS, the Compan
March 15, 2021	EX-3.3	Form of Amended and Restated Certificate of Incorporation, to be in effect upon closing of this offering. Exhibit 3.3 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF FINCH THERAPEUTICS GROUP, INC. Finch Therapeutics Group, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of the Delaware, hereby certifies that: ONE: The original name of this corporation was Finch Therapeutics Group, Inc. and the date of filing the original Certificate of In
March 15, 2021	EX-10.14	Amended and Restated Executive Employment Agreement by and between the registrant and Gregory D. Perry, dated as of March 12, 2021, to be effective upon the pricing of this offering. EX-10.14 13 d54314dex1014.htm EX-10.14 Exhibit 10.14 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT, dated as of March 12, 2021 (this “Agreement”), is made by and between Finch Therapeutics Group, Inc., a Delaware corporation (“FTG”, together with all subsidiaries and affiliates hereinafter referred to as the “Company”), and Gregory D.
March 15, 2021	EX-4.2	Form of Common Stock Certificate. Exhibit 4.2 DELAWARE SEAL FINCH THERAPEUTICS GROUP, INC. CORPORATE September 21, 2017 FT FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.001 PAR VALUE PER SHARE, OF Finch Therapeutics Group, Inc. transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of this Certificate properly endorsed. This Certificate is not valid until countersigned by the
March 15, 2021	EX-3.1	Amended and Restated Certificate of Incorporation, as amended and as presently in effect. Exhibit 3.1 FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF FINCH THERAPEUTICS GROUP, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Finch Therapeutics Group, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREB
March 15, 2021	EX-10.10	2021 Equity Incentive Plan and the forms of agreements thereunder. EX-10.10 9 d54314dex1010.htm EX-10.10 Exhibit 10.10 FINCH THERAPEUTICS GROUP, INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 11, 2021 APPROVED BY THE STOCKHOLDERS: MARCH 11, 2021 IPO DATE: , 2021 1. GENERAL. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such p
March 15, 2021	EX-10.2	Form of Indemnity Agreement between Finch Therapeutics Group, Inc. and its officers and directors (incorporated by reference to Exhibit 10.2 of the Registrant’s Registration Statement on Form S-1, as amended, filed March 18, 2021). EX-10.2 8 d54314dex102.htm EX-10.2 Exhibit 10.2 FORM OF INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , 20 between Finch Therapeutics Group, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or in other capaciti
March 15, 2021	EX-3.4	Form of Amended and Restated Bylaws, to be in effect upon closing of this offering. EX-3.4 5 d54314dex34.htm EX-3.4 Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF FINCH THERAPEUTICS GROUP, INC. (A DELAWARE CORPORATION) Table of Contents Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS’ MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meetings 1 Section 6. Spec
March 15, 2021	EX-1.1	Form of Lock up agreement (included as Exhibit A to the Underwriting Agreement, incorporated by reference to Exhibit 1.1 to the Issuer’s Registration Statement on Form S-1 (SEC 333-253622). Exhibit 1.1 FINCH THERAPEUTICS GROUP, INC. (a Delaware corporation) [●] Shares of Common Stock UNDERWRITING AGREEMENT Dated: [●], 2021 FINCH THERAPEUTICS GROUP, INC. (a Delaware corporation) [●] Shares of Common Stock UNDERWRITING AGREEMENT [●], 2021 BofA Securities, Inc. Jefferies LLC Evercore Group L.L.C. as Representatives of the several Underwriters c/o BofA Securities, Inc. One Bryant Park Ne
March 15, 2021	EX-10.12	Amended and Restated Executive Employment Agreement, by and between Finch Therapeutics Group, Inc. and Mark Smith, dated as of March 12, 2021 (incorporated by reference to Exhibit 10.12 of the Registrant’s Registration Statement on Form S-1, as amended, filed March 18, 2021). Exhibit 10.12 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT, dated as of March 12, 2021 (this ?Agreement?), is made by and between Finch Therapeutics Group, Inc., a Delaware corporation (?FTG?, together with all subsidiaries and affiliates hereinafter referred to as the ?Company?), and Mark Smith (the ?Executive?). WHEREAS, the Company
March 15, 2021	CORRESP	Cooley LLP 55 Hudson Yards New York, NY 10001-2157 t: (212) 479-6000 f: (212) 479-6275 cooley.com CORRESP 1 filename1.htm Divakar Gupta + 1 212 479 6474 [email protected] VIA EDGAR March 15, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Tara Harkins Ms. Kate Tillan Ms. Margaret Schwartz Ms. Laura Crotty Re: Finch Therapeutics Group, Inc. Registration Statement on Form S-1 Submitted February 26, 2021 File No. 333
March 5, 2021	CORRESP	[**] Certain confidential information contained in this document, marked by bracketed asterisks, has been omitted and filed separately with the Commission pursuant to 17 C.F.R. § 200.83. Cooley LLP 55 Hudson Yards New York, NY 10001-2157 t: (212) 47 Divakar Gupta +1 212 479 6474 [email protected] FOIA Confidential Treatment Request* Confidential Treatment Requested by Finch Therapeutics Group, Inc. in connection with Registration Statement on Form S-1 (File No. 333-253622) March 5, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Ms. Tara Harkins Ms. K
February 26, 2021	EX-10.9	First Amendment to Lease by and between Finch Therapeutics, Inc. and North River II LLC, dated as of January 20, 2017. EX-10.9 12 d54314dex109.htm EX-10.9 Exhibit 10.9 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (“First Amendment”) is made as of January 20, 2017 (“Effective Date”) by and between North River II LLC, a Delaware limited liability company (“Landlord”), with an address of 224 12th Avenue, New York, NY 10001 and NextBiome, Inc., a Delaware corporation, K.N.A. Finch Therapeutics, Inc., a Delaw
February 26, 2021	EX-21.1	Subsidiaries of the registrant. EX-21.1 13 d54314dex211.htm EX-21.1 Exhibit 21.1 SUBSIDIARIES Name Jurisdiction of Formation Finch Therapeutics, Inc. Delaware Finch Therapeutics Holdings, LLC Delaware Finch Research and Development, LLC Delaware
February 26, 2021	EX-10.4	Exclusive License Agreement by and between Crestovo, LLC and Arizona Science and Technology Enterprises LLC, dated as of July 3, 2017, as amended August 27, 2018 (incorporated by reference to Exhibit 10.4 of the Registrant’s Registration Statement on Form S-1, as amended, filed March 18, 2021). EX-10.4 7 d54314dex104.htm EX-10.4 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE FINCH THERAPEUTICS GROUP, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO FINCH THERAPEUTICS GROUP, INC. IF PUBLICLY DISCLOSED. Exhibit 10.4 EXECUTION COPY EXCLUSIVE LICENSE AGREEMENT This Exclusive License
February 26, 2021	EX-3.1	Amended and Restated Certificate of Incorporation, as amended and as presently in effect. EX-3.1 2 d54314dex31.htm EX-3.1 Exhibit 3.1 Delaware The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF INCORPORATION OF “FINCH THERAPEUTICS GROUP, INC.”, FILED IN THIS OFFICE ON THE TWENTY—FIRST DAY OF SEPTEMBER, A.D. 2017, AT 10:53 O’CLOCK A.M. A FILED COPY OF THIS CERTIFICATE HAS BEE
February 26, 2021	EX-10.8	Lease by and between NextBiome, Inc. and North River II LLC, dated as of December 21, 2015. Exhibit 10.8 THIS LEASE is made this 21st day of December 2015 (“Effective Date”), between North River II LLC, d/b/a North River Art a Delaware limited liability company (“Landlord”), and NextBiome, Inc., a Delaware corporation (“Tenant”). WITNESSETH: For and in consideration of the covenants herein contained and upon the terms and conditions herein set forth, the parties agree as follows: 1. Intr
February 26, 2021	CORRESP	Cooley LLP 55 Hudson Yards New York, NY 10001-2157 t: (212) 479-6000 f: (212) 479-6275 cooley.com Divakar Gupta + 1 212 479 6474 [email protected] VIA EDGAR February 26, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Tara Harkins Ms. Kate Tillan Ms. Margaret Schwartz Ms. Laura Crotty Re: Finch Therapeutics Group, Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted February 9, 2021 CIK No. 0
February 26, 2021	EX-4.1	Third Amended and Restated Stockholders Agreement, by and among Finch Therapeutics Group, Inc. and certain of its stockholders, dated September 2, 2020 (incorporated by reference to Exhibit 4.1 of the Registrant’s Registration Statement on Form S-1, as amended, filed March 18, 2021). EX-4.1 4 d54314dex41.htm EX-4.1 Exhibit 4.1 THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT THIS THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “Agreement”), is made and entered into as of September 2, 2020, by and among (i) Finch Therapeutics Group, Inc., a Delaware corporation (the “Company”), (ii) each holder of Common Stock listed on Schedule A under the heading “Common Stockholders
February 26, 2021	EX-10.6	Asset Purchase Agreement by and between Finch Therapeutics, Inc. and Microbiome Health Research Institute, Inc., dated as of November 19, 2020 (incorporated by reference to Exhibit 10.6 of the Registrant’s Registration Statement on Form S-1, as amended, filed March 18, 2021). CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE FINCH THERAPEUTICS GROUP, INC.
February 26, 2021	EX-10.7	LMIC License Agreement by and between Finch Therapeutics, Inc. and Microbiome Health Research Institute, Inc., dated as of November 19, 2020. EX-10.7 10 d54314dex107.htm EX-10.7 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE FINCH THERAPEUTICS GROUP, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO FINCH THERAPEUTICS GROUP, INC. IF PUBLICLY DISCLOSED. Exhibit 10.7 Execution Version LMIC LICENSE AGREEMENT by and between MICROBIO
February 26, 2021	EX-10.1	2017 Equity Incentive Plan, as amended, and the forms of agreements thereunder. Exhibit 10.1 FINCH THERAPEUTICS GROUP, INC. 2017 EQUITY INCENTIVE PLAN 1. Definitions As used in this 2017 Equity Incentive Plan, the following terms shall have the respective meanings set out below, unless the context clearly requires otherwise: 1.1. ?Accelerate,? ?Accelerated,? and ?Acceleration,? when used with respect to an Option, means that as of the time of reference such Option will become
February 26, 2021	EX-10.3	Exclusive Patent License Agreement by and between CIPAC Limited and Regents of the University of Minnesota, dated as of March 26, 2012, as amended July 10, 2014, October 23, 2014, December 13, 2016 and September 15, 2017. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE FINCH THERAPEUTICS GROUP, INC.
February 26, 2021	EX-3.2	Bylaws, as presently in effect. Exhibit 3.2 BYLAWS OF FINCH THERAPEUTICS GROUP, INC. a Delaware Corporation TABLE OF CONTENTS Page 1. Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 2. Meetings Of Stockholders 1 2.1 Annual Meeting 1 2.2 Meetings by Remote Communication 1 2.3 Notice of Meetings 1 2.4 Timing of Notice 1 2.5 Voting List 2 2.6 Special Meetings 2 2.7 Scope of Business at Special Meeting 2 2.8 Quorum 2 2.9 Quali
February 26, 2021	S-1	Power of Attorney (see signature page to the registration statement). Table of Contents As filed with the Securities and Exchange Commission on February 26, 2021 Registration Statement No.
February 26, 2021	EX-10.5	Amended and Restated Agreement by and between Finch Therapeutics, Inc. and Millennium Pharmaceuticals, Inc., dated as of October 21, 2019. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE FINCH THERAPEUTICS GROUP, INC.
February 9, 2021	EX-10.9	FIRST AMENDMENT TO LEASE Exhibit 10.9 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (?First Amendment?) is made as of January 20, 2017 (?Effective Date?) by and between North River II LLC, a Delaware limited liability company (?Landlord?), with an address of 224 12th Avenue, New York, NY 10001 and NextBiome, Inc., a Delaware corporation, K.N.A. Finch Therapeutics, Inc., a Delaware corporation (?Tenant?). WHEREAS,
February 9, 2021	EX-10.8	[SIGNATURE PAGE FOLLOWS] EX-10.8 10 filename10.htm Exhibit 10.8 THIS LEASE is made this 21st day of December 2015 (“Effective Date”), between North River II LLC, d/b/a North River Art a Delaware limited liability company (“Landlord”), and NextBiome, Inc., a Delaware corporation (“Tenant”). WITNESSETH: For and in consideration of the covenants herein contained and upon the terms and conditions herein set forth, the parties
February 9, 2021	DRS/A	- Table of Contents As confidentially submitted to the Securities and Exchange Commission on February 8, 2021 This Amendment No.
February 9, 2021	EX-10.7	LMIC LICENSE AGREEMENT by and between MICROBIOME HEALTH RESEARCH INSTITUTE, INC. FINCH THERAPEUTICS, INC. November 19, 2020 Exhibit 10.7 Execution Version LMIC LICENSE AGREEMENT by and between MICROBIOME HEALTH RESEARCH INSTITUTE, INC. and FINCH THERAPEUTICS, INC. November 19, 2020 TABLE OF CONTENTS 1.??DEFINITIONS 3 2.??LICENSE GRANTS AND TECHNOLOGY TRANSFER 10 2.1. License from Finch to OpenBiome 10 2.2. New In-Licenses 11 2.3. Independent and Competitive Activities 11 2.4. OpenBiome Sublicensees 11 2.5. No Implied R
February 9, 2021	EX-3.1	Delaware The First State EX-3.1 2 filename2.htm Exhibit 3.1 Delaware The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF INCORPORATION OF “FINCH THERAPEUTICS GROUP, INC.”, FILED IN THIS OFFICE ON THE TWENTY—FIRST DAY OF SEPTEMBER, A.D. 2017, AT 10:53 O’CLOCK A.M. A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARD
February 9, 2021	EX-10.6	ASSET PURCHASE AGREEMENT by and between FINCH THERAPEUTICS, INC., MICROBIOME HEALTH RESEARCH INSTITUTE, INC. DATED AS OF NOVEMBER 19, 2020 EX-10.6 8 filename8.htm Exhibit 10.6 Execution Version ASSET PURCHASE AGREEMENT by and between FINCH THERAPEUTICS, INC., and MICROBIOME HEALTH RESEARCH INSTITUTE, INC. DATED AS OF NOVEMBER 19, 2020 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND TERMS 1 Section 1.1. Definitions 1 Section 1.2. Other Definitional Provisions 16 ARTICLE II PURCHASE AND SALE; GRANT OF LICENSES 16 Section 2.1. Purchase
February 9, 2021	EX-10.4	EXCLUSIVE LICENSE AGREEMENT EX-10.4 6 filename6.htm Exhibit 10.4 EXECUTION COPY EXCLUSIVE LICENSE AGREEMENT This Exclusive License Agreement (“Agreement”) is made and entered into as of July 3, 2017 (the “Effective Date”) between Arizona Science and Technology Enterprises LLC, an Arizona limited liability company d/b/a Arizona Technology Enterprises (“AzTE”) and Crestovo LLC, a Delaware limited liability corporation (“Compan
February 9, 2021	EX-3.2	BYLAWS FINCH THERAPEUTICS GROUP, INC. a Delaware Corporation EX-3.2 3 filename3.htm Exhibit 3.2 BYLAWS OF FINCH THERAPEUTICS GROUP, INC. a Delaware Corporation TABLE OF CONTENTS Page 1. Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 2. Meetings Of Stockholders 1 2.1 Annual Meeting 1 2.2 Meetings by Remote Communication 1 2.3 Notice of Meetings 1 2.4 Timing of Notice 1 2.5 Voting List 2 2.6 Special Meetings 2 2.7 Scope of Business at Special Meeting 2
February 9, 2021	EX-21.1	SUBSIDIARIES Name Jurisdiction of Formation Finch Therapeutics, Inc. Delaware Finch Therapeutics Holdings, LLC Delaware Finch Research and Development, LLC Delaware Exhibit 21.1 SUBSIDIARIES Name Jurisdiction of Formation Finch Therapeutics, Inc. Delaware Finch Therapeutics Holdings, LLC Delaware Finch Research and Development, LLC Delaware
February 9, 2021	EX-10.5	FINCH THERAPEUTICS, INC. MILLENNIUM PHARMACEUTICALS, INC. AMENDED AND RESTATED AGREEMENT EX-10.5 7 filename7.htm Exhibit 10.5 FINCH THERAPEUTICS, INC. AND MILLENNIUM PHARMACEUTICALS, INC. AMENDED AND RESTATED AGREEMENT TABLE OF CONTENT 1. DEFINITIONS 3 2. LICENSES; PROPRIETARY RIGHTS 17 3. GOVERNANCE; INFORMATION SHARING 23 4. DEVELOPMENT PROGRAM 27 5. REGULATORY MATTERS 31 6. MANUFACTURE AND SUPPLY 32 7. COMMERCIALIZATION 34 8. CONSIDERATION; PAYMENT 34 9. PATENT 40 10. CONFIDENTIALI
February 9, 2021	EX-10.3	UNIVERSITY OF MINNESOTA EXCLUSIVE PATENT LICENSE AGREEMENT EX-10.3 5 filename5.htm Exhibit 10.3 UNIVERSITY OF MINNESOTA EXCLUSIVE PATENT LICENSE AGREEMENT THIS EXCLUSIVE PATENT LICENSE AGREEMENT (this “Agreement”) is made by and between Regents of the University of Minnesota, a constitutional corporation under the laws of the state of Minnesota, having a place of business at 1000 Westgate Drive, Suite 160, St. Paul, Minnesota 55114 (the “University”), and
February 9, 2021	EX-4.1	THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT EX-4.1 4 filename4.htm Exhibit 4.1 THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT THIS THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “Agreement”), is made and entered into as of September 2, 2020, by and among (i) Finch Therapeutics Group, Inc., a Delaware corporation (the “Company”), (ii) each holder of Common Stock listed on Schedule A under the heading “Common Stockholders” (the “E
February 8, 2021	DRSLTR	* * * * Divakar Gupta + 1 212 479 6474 [email protected] VIA EDGAR February 8, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Tara Harkins Ms. Kate Tillan Ms. Margaret Schwartz Ms. Laura Crotty Re: Finch Therapeutics Group, Inc. Draft Registration Statement on Form S-1 Submitted on December 28, 2020 CIK No. 0001733257 Ladies
December 28, 2020	DRS	- Table of Contents As confidentially submitted to the Securities and Exchange Commission on December 23, 2020.

FNCH / Finch Therapeutics Group, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)